Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9030 Authors: Enriqueta Felip, Matthew...
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9006 Authors: Naoki Furuya, Tatsuro...
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: LBA4 Authors: Gilberto Lopes, Yi-Long...
Pembrolizumab Improves Survival, Reduces Toxicity Over Chemotherapy in Low PD-L1–Expressing NSCLC
23 septembra, 2020 4:52 pmJune 4, 2018 Pembrolizumab significantly improved overall survival (OS) compared with platinum-based chemotherapy as first-line therapy for patients with...
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 105 Authors: Luis G. Paz-Ares,...
Frontline Pembrolizumab and Chemotherapy a New Standard of Care in Metastatic Squamous NSCLC
23 septembra, 2020 4:52 pmJune 3, 2018 Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in...
Karcinóm pľúc na ASCO 2018
23 septembra, 2020 4:52 pmÚvod Konferencia ASCO 2018 (ďalej iba ASCO 2018) sa niesla v znamení imunoterapie celým spektrom nádorových ochorení, zvlášť to však platilo...
First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3505 Authors: Filippo Pietrantonio, Federica Morano,...
Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3501 Authors: Yong Sang Hong, Sun...
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4019 Authors: Ghassan K. Abou-Alfa, Tim...